Oncology Pharma
Conducting Interviews and Presentations with Investors to
Pursue Next Steps to Forward The
Development Process of Nanoemulsion Drug Delivery System
San Francisco, CA -- July 12, 2022 -- InvestorsHub NewsWire --
Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The
Company") is furthering progress in discussions with investors and
developing the financing model towards the next step of the
development process with its Nanoemulsion drug delivery
system. The Company is confident that it will progress
towards this next step.
The early feasibility study was intended to serve as a
demonstration that the development team possessed the capability of
formulating research-scale nanoemulsion formulations of
dactinomycin. Initial characterization of these formulations
would be carried out to demonstrate that the nanoemulsion
formulation possessed several desirable characteristics that made
them suitable candidates for further nonclinical development.
As stated the Company is confident these steps were met and
looks forward to moving ahead.
Essentially, all of the specific aims under the scope of this
project were met. The capability to formulate nanoemulsions
that incorporate the active pharmaceutical ingredient,
dactinomycin, was demonstrated. Specifically, the study
identified two formulations feasible for further development.
The capability to be able to innovate and make progress in this
early stage demonstrates the team's ability to identify
developmental goals and overcome formulation challenges to produce
a drug formulation with suitable characteristics for further,
formal nonclinical development. These characteristics include
the ability for the nanoemulsion to incorporate the majority of
available drug into the lipid nanoparticles, a demonstrated
release-over-time profile, and stability during storage.
Additionally, test methods were established at independent contract
laboratories to support basic formulation characterization and
accurately detecting the drug concentration in control and test
formulations in support of future nonclinical studies.
ABOUT ONCOLOGY PHARMA, INC.
ONCOLOGY PHARMA, INC. (OTC PINK:ONPH) (the "Company") is currently
engaging in research and development of therapeutics for oncology
and prides itself for having a world-class Advisory Board that
keeps the Company in the forefront of developing technologies in
cancer research, biotechnology, and healthcare.
FORWARD-LOOKING STATEMENTS
Certain of the matters discussed in this announcement contain
forward-looking statements that involve material risks to and
uncertainties in the Company's business that may cause actual
results to differ materially from those anticipated by the
statements made herein. Such risks and uncertainties include risks
related to licensing arrangements and joint ventures, including the
need to negotiate the definitive agreements for the relationships;
possible failure to realize anticipated benefits of business
relationships; and, costs of providing funding to these business
relationships. Other risks and uncertainties relating to the
Company include, among other things, current negative operating
cash flows and a need for additional funding to finance our
operating plan; the terms of any further financing, which may be
highly dilutive and may include onerous terms; unexpected costs and
operating deficits, and lower than expected sales and revenues;
uncertain willingness and ability of customers to adopt new
technologies and other factors that may affect further market
acceptance; adverse economic conditions; adverse results of any
legal proceedings; the volatility of our operating results and
financial condition; inability to attract or retain qualified
senior management personnel, including sales and marketing
personnel; our ability to establish and maintain the proprietary
nature of our technology through the patent process, as well as our
ability to possibly license from others patents and patent
applications necessary to develop products; the Company's ability
to implement its long range business plan for various applications
of its technology; the Company's ability to enter into agreements
with any necessary marketing and/or distribution partners and with
any strategic or joint venture partners; the impact of competition;
the obtaining and maintenance of any necessary regulatory
clearances applicable to applications of the Company's technology;
management of growth; and, other risks and uncertainties. This is
not a solicitation to buy or sell securities and does not purport
to be an analysis of the Company's financial position.
CONTACTS:
For additional Information, please contact the Oncology Pharma
at:
One Sansome Street, Suite 3500
San Francisco, CA 94104
Phone: 415-869-1038
Fax: 415-946-8801
website: www.oncology-pharma.com
email: info@oncology-pharma.com